October 02, 2018 CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announced that it has entered into a joint research agreement with Q Therapeutics, Inc., a privately held developer of clinical-stage cell therapies for central nervous system
CENTENNIAL, Colo., Sept. 25, 2018 /PRNewswire/ -- AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced two presentations on the use of biologics in spinal fusion surgery at AlloSource's booth #2031 at the North American Spine Society (NASS) Annual Meeting on Thursday, September 27. Dr. Wellington K. Hsu will present
SCHLIEREN (ZURICH), Switzerland, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced the formation of its Strategic Advisory Board (SAB). The newly-formed SAB will work closely with Kuros’ leadership team to guide the strategic direction of the company. The SAB is assembled from key-opinion-leading surgeons and academic research experts, specialized in the
September 25, 2018 FORT WORTH, Texas--(BUSINESS WIRE)--Fort Worth-based Reinvent Biologics announced the appointment of David Drez Jr., MD as Chief Medical Officer. As Chief Medical Officer, Drez will provide strategic leadership on all of Reinvent Biologics medical education and research activities. He will research and track current clinical trends and provide training and support to
September 24, 2018 Artoss, Inc. is pleased to announce the hiring of William “Billy” Lapp as Director of Sales, East Coast. In this role, Billy will be responsible for growing the sales of NanoBone® Bone Graft in the region from Maine to South Carolina and west to Ohio and for identifying, training, and managing independent
SAN DIEGO, Sept. 24, 2018 /PRNewswire/ -- NuVasive, Inc. (NASDAQ :NUVA ), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the U.S. commercial launch of three new biologics offerings to include traditional bone allograft, amniotic membrane DS and additional form factors to the current PropelTM DBM product line. This portfolio
HOUSTON, Sept. 24, 2018 /PRNewswire/ -- SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of spinal discs using Human Dermal Fibroblasts, today announced it will be showcasing its fibroblast-based cell therapy product CybroCell at the North American Spine Society (NASS) 2018 Annual Meeting Sept. 26 - 29 in Los Angeles. The company recently published data in The Spine Journal that suggest
MARIETTA, Ga., Sept. 20, 2018 /PRNewswire/ -- The Board of Directors (the "Board") of MiMedx Group, Inc. (Nasdaq :MDXG ), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it has determined that the previously announced separations of four senior MiMedx executives – Parker H. Petit, William C. Taylor, Michael J. Senken, and John E. Cranston (collectively, the "Separated Employees")
September 21, 2018 COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Synergy Biomedical, LLC, a developer of innovative biomaterial products, announced today that it has received FDA 510(k) clearance and is proceeding with a full commercial launch of BIOSPHERE® MIS PUTTY. BIOSPHERE® MIS PUTTY utilizes a pre-loaded bone graft cannula and trigger-based delivery system specifically designed for the unique challenges of minimally invasive
COLUMBIA, Md., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces that GrafixPL PRIME™, a human placental membrane that can be stored at ambient temperatures, launches for sale on October 1, 2018. The structural matrix, growth factors,
